Cormorant Asset Management, LLC - Insider Trading Tracker

Apellis Pharmaceuticals, Inc.

US ˙ NasdaqGS ˙ US03753U1060

Introduction

This page provides a comprehensive analysis of the known insider trading history of Cormorant Asset Management, LLC. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

See Highest Ranking Insiders

Companies with Reported Insider Positions

The SEC filings indicate Cormorant Asset Management, LLC has reported holdings or trades in the following companies:

Security	Title	Latest Reported Holdings
		0
		987,689
US:DRUG / Bright Minds Biosciences Inc.	10% Owner	1,059,331
		1,629,529
US:CRBP / Corbus Pharmaceuticals Holdings, Inc.	10% Owner	2,375,000
US:EYPT / EyePoint Pharmaceuticals, Inc.	10% Owner	8,325,000
US:IMRX / Immuneering Corporation	10% Owner	2,895,273
	10% Owner	11,231,000
US:MLTX / MoonLake Immunotherapeutics	10% Owner	8,494,151
US:AMAM / Ambrx Biopharma Inc.	10% Owner	69,465,823
US:GRNA / GreenLight Biosciences Inc		0
US:BMEA / Biomea Fusion, Inc.	10% Owner	3,570,872
US:ERAS / Erasca, Inc.	Director	10,813,246
US:VIGL / Vigil Neuroscience, Inc.		0
US:VTYX / Ventyx Biosciences, Inc.		0
US:PYXS / Pyxis Oncology, Inc.		0
US:TYRA / Tyra Biosciences, Inc.		0
US:ICVX / Icosavax, Inc.		0
US:AVTE / Aerovate Therapeutics, Inc.		0
US:ELEV / Elevation Oncology, Inc.		0
US:GLUE / Monte Rosa Therapeutics, Inc.		0
US:VERV / Verve Therapeutics, Inc.		0
		0
US:DSGN / Design Therapeutics, Inc.		0
US:RXDX / Prometheus Biosciences Inc		0
US:BCAB / BioAtla, Inc.		0
US:OLMA / Olema Pharmaceuticals, Inc.		0
US:AVIR / Atea Pharmaceuticals, Inc.		0
US:AKUS / Akouos Inc		0
US:RNA / Avidity Biosciences, Inc.		0
US:TPTX / Turning Point Therapeutics Inc	10% Owner	3,122,367
US:AXNX / Axonics, Inc.	10% Owner	0
US:KZR / Kezar Life Sciences, Inc.	10% Owner	0
US:KNSA / Kiniksa Pharmaceuticals, Ltd.	10% Owner	0
	10% Owner	3,300,000
US:APLS / Apellis Pharmaceuticals, Inc.	10% Owner	0
US:CLSD / Clearside Biomedical, Inc.	10% Owner	3,976,416
US:CLRB / Cellectar Biosciences, Inc.	10% Owner	1,060,000

How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Cormorant Asset Management, LLC. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases APLS / Apellis Pharmaceuticals, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in APLS / Apellis Pharmaceuticals, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date	Ticker	Insider	Reported Shares	Reported Price	Adjusted Shares	Adjusted Price	Cost Basis	Days to Max	Price at Max	Max Profit ($)	Max Return (%)
2017-11-13	APLS	Cormorant Asset Management, LLC	1,071,428	14.0000	1,071,428	14.0000	14,999,992	154	30	17,142,848	114.29